An interventional study of DETECTRA and Standard of Care (SOC) in Rheumatic Disorder and Rheumatoid Arthritis (RA), sponsored by Centre Hospitalier Universitaire Vaudois. Not yet recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Centre Hospitalier Universitaire Vaudois · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 362 studies in Arthritis, Rheumatoid with a site in Germany — 27 open to participants now, 50 under way, 3 of them phase 3. Arthritis, Rheumatoid · Germany.
Among the 362 studies in Arthritis, Rheumatoid with a site in Germany, this one is the 125th largest by planned enrollment of the 297 interventional ones that give a count, is one of 7 that started in 2026, is one of 19 with no phase, reaches primary completion later than 38 of the 49 other live ones, and was the 359th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →27 of the 362 studies in Arthritis, Rheumatoid with a site in Germany are open now. Recruiting first, the newest first:
Diabetes Free, Inc. · Sites in Germany
Ages 18+
Bristol-Myers Squibb · Sites in Germany, United States, Belgium and 8 more countries
Ages 18–65
Quell Therapeutics Limited · Sites in Germany, Spain, United Kingdom
Ages 18+
AstraZeneca · Sites in Germany, United States, Australia and 3 more countries
Ages 18–75
AstraZeneca · Sites in Germany, United States, Argentina and 14 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
362 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 108 · Phase 3 116 · Phase 4 22
First in 1998; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 320 is above the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 259 across the 297 interventional studies, 585 across the 65 observational. Of the 305 that completed or were terminated, 198 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
327 of 362 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire Vaudois is the lead sponsor of 208 studies on the registry; 48 are open to participants now.
Centre Hospitalier Universitaire Vaudois has 2 studies filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
13 of the studies in Arthritis, Rheumatoid with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02337244Zimmer, GmbHZimmer POLAR Persona - TKA (EMEA Study) | 2026-12 |
| NCT06972446AbbVieA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | 2027-02 |
| NCT06831994Universitätsklinikum Hamburg-EppendorfDigital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity | 2027-02-28 |
| NCT06902519Gilead SciencesStudy of GS-0151 in Participants With Rheumatoid Arthritis | 2027-03 |
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
Add all 13 to your calendar (.ics) → With an account.
Among the 362 studies in Arthritis, Rheumatoid with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if the DETECTRA remote monitoring platform can help clinicians detect rheumatoid arthritis (RA) disease flares earlier and more reliably, as well as identify response and non-response or insufficient response to treatment, compared with standard care. The study will include patients with RA and will follow them for 12 months.
The main questions it aims to answer are:
In patients with remission or low disease activity (DAS28-CRP ≤ 2.6), does remote monitoring with patient-reported outcomes and self-performed imaging using DETECTRA enable earlier detection of disease flares compared with standard care? In patients with higher disease activity (DAS28-CRP > 2.6) who have switched medication, does DETECTRA enable earlier and more reliable identification of response and non-response or insufficient response to treatment compared with standard care?
Researchers will compare the DETECTRA intervention groups with standard-of-care control groups to see whether remote monitoring enables earlier and more reliable detection of changes in disease activity and treatment response.
Participants will:
Be assigned to a Low Disease Activity (LDA) or High Disease Activity (HDA) substudy based on their DAS28-CRP score at baseline.
Be randomly assigned within their substudy to either the DETECTRA remote monitoring group or the standard-of-care group.
In the DETECTRA group, regularly provide patient-reported outcomes and perform self-imaging of their hands remotely using the DETECTRA application.
Attend standard clinical assessments and be followed for 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inclusion criteria for being randomized within the LDA study: • DAS28-CRP ≤ 2.6 Participants in this group will receive standard of care treatment and in addittion receive the DETECTRA application which they will use on a weekly basis during 12months.
Device: DETECTRA
Inclusion criteria for being randomized withing the HDA study: * DAS28-CRP \> 2.6 * A change or start of any DMARDs treatment Participants in this arm will receive standard of care treatment and in addition will use the DETECTRA app on a weekly basis for 12months.
Device: DETECTRA
Inclusion criteria for being randomized within the LDA study: • DAS28-CRP ≤ 2.6 Participants in this arm will receive the standard of care treatment.
Other: Standard of Care (SOC)
Inclusion criteria for being randomized withing the HDA study: * DAS28-CRP \> 2.6 * A change or start of any DMARDs treatment Particiapnts in this arm will receive standard of care treatment.
Other: Standard of Care (SOC)
DETECTRA is a mobile application to be used on a weekly basis by patients where they submit hand images as well as report patient reported outcomes.
Standard of care for rheumatoid arthritis informed by EULAR guidelines.
Time to response to treatment detection
HDA groups: •Time in (days) from study enrolment to response to treatment detection in RA (defined as DAS28 change of \> 0.6 between 2 visits / CDAI improvement ≥ 6 points to baseline at 3 months and current CDAI remaining ≤ 10 points) comparing the DETECTRA group to the standard care group.
Time frame: From study enrollment to the end of study at 12months.
Time to flare detection
LDA groups: •Time (in days) from study enrolment to confirmed flare (defined as Change of Clinical Disease Activity Index (CDAI) ≥ 4.5 points from last visit \& current CDAI \> 10 or change of DAS28-CRP \> 1.2 and the current DAS28 ≥ 2.6) and
Time frame: From enrollment to the end of study at 12months.
Diagnostic accuracy
Diagnostic accuracy of the DETECTRA system to differentiate between presence and absence of a flare / non-response / insufficient response to treatment (as defined by clinical examination) will be assessed using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).
Time frame: From study enrollment until end of study at 12months.
Sensitivity
Missed flares/non-response / insufficient response to treatment of clinical arthritis in the intervention group: This endpoint will be assessed if a patient comes for a visit based on his request and in any visit. Any confirmed flare is classified as a missed flare if a patients request a visit (or in a planned visits) without that the physician had previously recognized signs via the dashboard of a potential flare.
Time frame: From study enrollment until end of study at 12months.
Specificity
False flares/detection of non-response / insufficient response to treatment in the intervention group will be assessed at any interim visit and is reported if a patient got flagged via the dashboard, came in for confirmation but does not get confirmation of a flare or of a non-response / insufficient response to treatment.
Time frame: From enrollment until end of study at 12months.
Adherence
Percentage of submissions on the application (totally expected submissions = every week until end of trial) for patients in the DETECTRA intervention group.
Time frame: From enrollment until the end of study at 12months.
Adherence
Average amount of reminders (calls by the study nurse but not the automatic reminders via the app) per patient needed during the duration of the study (1year). For participants in the DETECTRA arms.
Time frame: From enrollment until the end of study at 12months.
Cost-effectiveness estimates
The primary outcome of interest for the health economic evaluation is cost-effectiveness, expressed as the incremental cost per Quality-Adjusted Life Year (QALY) gained through the use of DETECTRA compared to standard of care. Data for the evaluation will be collected from both the DETECTRA system and clinical records during the trial. Through the app, patients will report PROs including self-assessed joint counts (tender and swollen), global pain and stiffness scores (via VAS-like scales), medication use, free-text symptom notes, and joint-specific pain reports. At the clinic level, data will be collected on the timing and number of visits, formal RA diagnoses, and DMARD treatment initiations and changes. These trial-derived endpoints, particularly time-to-flare detection and amount of visits, will inform a Markov model to extrapolate long-term costs and outcomes beyond the trial period.
Time frame: From enrollment until end of study at 12months.
Number of consultations
LDA group only: Difference in number of consultations within the 12months study period in the DETECTRA group as compared to the standard group.
Time frame: From enrollment until the end of study at 12months.
Difference in DAS28-CRP
After 12 months will be assessed by a trained rheumatologist in the DETECTRA group as compared to the standard group.
Time frame: From enrollement until the end of study at 12months.
Difference in Simplified Disease Activity Index (SDAI)
Difference in SDAI after 12 months will be assessed by a trained rheumatologist in the DETECTRA group as compared to the standard group.
Time frame: From enrollment until end of study at 12months.
Remission rates
Percentage of patients in remission after 12 months, will be assessed by a trained rheumatologist in the DETECTRA group as compared to the standard group.
Time frame: From enrollment until the end of study at 12months.
Sensitivity to change
Sensitivity to change will be calculated for the biomarker (FFI) using the Standardized Response Mean (SRM), defined as the mean change from baseline to follow-up divided by the standard deviation of the change scores.
Time frame: From enrollment until the end of study at 12months.
Patient empowerment
Regular self-reporting and feedback may increase perceived empowerment, trust in care, and shared decision-making (to be measured via PGIC).
Time frame: From enrollment until the end of study at 12months.
Mental health & Quality of Life:
For diagnosed patients, reassurance from remote monitoring and reduced flare anxiety may improve mental health (measured via SF-36).
Time frame: From enrollment until the end of study at 12months.
Usability and acceptance
This will be measured with the System Usability Scale (SUS) at the end of the trial within patients and HCPs who were using the app or the dashboard during the trial.
Time frame: From enrollment until the end of study at 12months.
Exploratory validation of additional imaging-derived metrics (e.g., finger joint geometry, patterns, motility)
Images and videos from any time-point of the investigation taken via the DETECTRA system will be used to support future enhancements of DETECTRA and the algorithms of the system.
Time frame: From enrollment until the end of study at 12months.
Diagnostic accuracy FFI
Diagnostic accuracy of the FFI to differentiate between presence and absence of synovitis (as defined by clinical examination and or ultrasound) will be assessed using the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).
Time frame: From enrollment until the end of study at 12months.
Thermal imaging dataset construction
• Data completeness: The number of valid thermal images successfully linked with their corresponding comprehensive set of clinical, demographic, laboratory, and ultrasound reference data.
Time frame: From enrollment until the end of study at 12months.
Thermal imaging
Data quality: Assessment of image technical quality (e.g., image noise, hand position, absence of artifacts) to ensure suitability for future image processing.
Time frame: From enrollment until the end of study at 12months.
Thermal imaging
Dataset integrity: The successful compilation of a structured dataset suitable for the development and validation of artificial intelligence models
Time frame: From enrollment until the end of study at 12months.
Plan to share: No
Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.
Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 25 months is close to that.
Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire Vaudois →